Lawmakers slam slow progress on UK drug pricing overhaul

LONDON (Reuters) – British lawmakers have criticized the government’s failure to detail a new system for medicines pricing that is due to be introduced next January, saying lack of clarity is creating uncertainty for industry and doctors. The House of Commons Health Committee called on the government on Wednesday to make clear its plans by the end of March 2013. “There has been extensive discussion of the principle of value-based pricing but it remains a source of concern that so little progress has been made on defining this nebulous concept,” the committee said in a report. …

European court rejects three UK faith bias complaints

Nadia Eweida poses for a photograph in the Temple Church in LondonSTRASBOURG (Reuters) – Europe's top human rights court ruled on Tuesday that equality laws and safety concerns trumped religious freedom in three cases where British Christians were sacked or sanctioned for expressing their beliefs at work. The European Court of Human Rights (ECHR) ruled employers did not violate the religious rights of a registrar who refused to officiate for civil partnerships of same-sex couples and a counselor deemed unwilling to offer sex therapy for gays. It also turned down an appeal by a nurse whose hospital barred her from wearing a cross around her neck. …

UK backs Lucentis for new use after Novartis cuts price

LONDON (Reuters) – Britain’s healthcare cost watchdog has given its backing to eye drug Lucentis to treat diabetes-related problems after Swiss drugmaker Novartis offered it at a discount to the National Health Service. The National Institute for Health and Clinical Excellence (NICE), in a reversal of an earlier decision, said on Friday Lucentis should now be available for patients with diabetic macular oedema (DMO). Lucentis is already approved by NICE to treat wet age-related macular degeneration. …

Fewer poor cancer patients referred for drug trials

NEW YORK (Reuters Health) – Among people with advanced cancer, poorer patients are less likely to be referred for clinical trials of experimental drugs, a new study from the UK suggests. Because those early trials will eventually help regulators decide if drugs should be approved for a wider population, it’s important that test patients be representative of people the medications are designed to treat, researchers said. …

1 2 3 9